Pharvaris’ USD 190 Million IPO

NautaDutilh advised Pharvaris on the deal. Loyens & Loeff advised Morgan Stanley, BofA Securities and SVB Leerink.

Pharvaris N.V. announced the pricing of its underwritten IPO for an amount up to USD 190 million in new common shares.

Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, on 4 February 2021 announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million.

Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,240,575 ordinary shares at the public offering price less underwriting discounts and commissions. This over-allotment option was exercised on 5 February 2021 in full. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on 8 February 2021 under the symbol “PHVS.”

Morgan Stanley, BofA Securities, and SVB Leerink acted as joint book-running managers in connection with the IPO of Pharvaris on NASDAQ

The NautaDutilh team included Paul van der Bijl (Picture), Sanne Meester, Mariëlle van Nimwegen, Mirjam von Meijenfeldt, Joppe Schoute and Daan Hagelstein.

The Loyens & Loeff N.V. team included Jelmer Kalisvaart, Marrco Toni, Rik Walschot, Ingrid Hijdra, Bart Wingen and Victor van Dooren.

Involved fees earner: Ingrid Hijdra – Loyens & Loeff; Jelmer Kalisvaart – Loyens & Loeff; Marco Toni – Loyens & Loeff; Victor van Dooren – Loyens & Loeff; Rik Walschot – Loyens & Loeff; Bart Wingen – Loyens & Loeff; Daan Hagelstein – NautaDutilh; Sanne Meester – NautaDutilh; Joppe Schouten – NautaDutilh; Paul van der Bijl – NautaDutilh; Mariëlle van Nimwegen – NautaDutilh; Mirjam von Meijenfeldt – NautaDutilh;

Law Firms: Loyens & Loeff; NautaDutilh;

Clients: Bank of America Merrill Lynch; Morgan Stanley; Pharvaris; SVB Leerink LLC;